Basel, Switzerland, July 21, 2010 (ots/PRNewswire) - New data show that Avastin(R) (bevacizumab) based therapy provides a median overall survival (OS) of 14.6 months with a range of chemotherapies routinely used in clinical practice and in a broad population of patients with advanced non-small cell lung cancer ...
Basel, Switzerland, June 18, 2010 (ots/PRNewswire) - Roche (SIX: RO, ROG; OTCQX: RHHBY) (http://www.roche.com/investors.htm) today announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic Juvenile ...
Basel, Switzerland, March 19, 2010 (ots/PRNewswire) - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely ...
Basel, Switzerland (ots/PRNewswire) - - Roche to Present new Results That Could Offer a Better Future to Women With Early and Very Advanced Breast Cancer, at the CTRC-AACR San Antonio Breast Cancer Symposium Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early ...
Basel, Switzerland (ots/PRNewswire) - - Nearly 150 Abstracts Covering New Tumour Types, New Patient Groups and Existing Indications to Feature in ECCO-ESMO Program Roche will present encouraging results from nearly 150 scientific studies investigating use of its major cancer medicines at ECCO 15 ESMO 34, which opens in Berlin, Germany today. Overall ...
Basel (ots/PRNewswire) - - For non-US, non-UK and non-Austrian Media Patients with advanced (metastatic) breast cancer will be able to benefit from treatment with Avastin (bevacizumab) as a result of a new broader label recommendation in Europe, Roche announced today. The positive opinion issued by the ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US Media Only New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ('prophylaxis') with Valcyte (oral valganciclovir), ...
Basel, Switzerland (ots/PRNewswire) - - PLX4032 (R7204) Phase I Results Offer Hope of First Highly Effective Drug in Melanoma Along With Companion Diagnostic - For Non-US Media Only Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising ...
Basel, Switzerland (ots/PRNewswire) - - For ex-US Media Only - Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin(R) (bevacizumab) ...
Basel, Switzerland (ots/PRNewswire) - - RIBBON-1 Study Confirms Benefit of Avastin in Treating HER2-Negative Breast Cancer - For Non-US, Non-UK and Non-Austrian Media Results from the phase III RIBBON-1 study presented today at ASCO showed that patients with advanced HER2-negative breast cancer ...
Basel, Switzerland (ots/PRNewswire) - - Mircera Maintained Haemoglobin Levels in Significantly More Patients With CKD on Dialysis Data from the first head-to-head study in patients with chronic kidney disease (CKD) on dialysis who need treatment for renal anaemia have demonstrated that Mircera(R) (methoxy ...
Basel, Switzerland (ots/PRNewswire) - - EMBARGOED: Not for publication until: 14 May at 23:00 BST More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way cancer is treated for patients with inoperable stomach cancer; advanced melanoma; lung and breast cancers. To view the Multimedia News ...
BASEL, Switzerland, BRISBANE, California and PRINCETON, New Jersey, April 25 (ots/PRNewswire) -- - Combination of R7227, Protease Inhibitor, and R7128, Nucleoside Polymerase Inhibitor, Shows Significant Potency in Reducing Viral Load in Patients With Hepatitis C Roche (SWX: RO, ROG; OTCQX: RHHBY), ...
Basel, Switzerland (ots/PRNewswire) - - New Phase III Study Will Evaluate if Tarceva is Superior to Traditional Chemotherapy in First Line Treatment of key Group of Patients Roche and the Spanish Lung Cancer Group (SLCG) today announced their collaboration on the first phase III trial to investigate Tarceva(R) (erlotinib) in lung cancer patients with genetic ...
Basel, Switzerland (ots/PRNewswire) - New data published today in a major peer-reviewed journal, Annals of Internal Medicine, show that re-treatment with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) provides previously-treated hepatitis C patients a second chance for a cure. The study results ...
Basel, Switzerland (ots/PRNewswire) - - Contraindication for Patients With Untreated Brain Metastases Removed - For non-US, UK and Austrian Media Only The European Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin(R) (bevacizumab) in some patients whose primary cancer has spread to their brain (brain metastases). The label change is based on safety ...
Basel, Switzerland (ots/PRNewswire) - - Immune-Boosting Effect of Pegasys Provides Patients With the Chance for a Clinical Cure FOR NON-UK MEDIA New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys(R) (peginterferon alfa-2a) ...
Basel, Switzerland (ots/PRNewswire) - - Doubling Duration of Valcyte Therapy Provides Significant Benefit to Patients Compared to Current Standard of Care - For Non-US Media Only Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative therapy ...
Basel, Switzerland (ots/PRNewswire) - - Tamiflu Remains Fully Effective Against 94 Percent of Circulating Influenza Viruses in Europe Latest surveillance data coming through the European Centre for Disease Prevention and Control (ECDC) from virologists and clinicians indicates that the influenza A(H3N2) virus is the predominant strain in Europe so far this ...
Basel, Switzerland (ots/PRNewswire) - - Roche Medicines Offer Improved Ways of Fighting the Leading Cause of Cancer Death in Women New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) ...
Basel, Switzerland (ots/PRNewswire) - - For non-US and non-UK Media Only - Long-term Results From a Phase III Study Highlight the Beneficial Role of MabThera in Patients With Recurrent or Resistant Disease Data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US Media Only - Abstract 234 - Roche and GlycArt Showcase Promising Early Results for its Next-Generation Lymphoma Treatment, R7159/GA101 Data presented for the first time today, at the 50th Annual Meeting of the American Society of Hematology (ASH), ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US and Non-UK Media Only - Abstract Number: 1 - New Phase III Data Suggest Potential Role for MabThera in Treating Blood Disorder New data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today, show that people living ...
Basel, Switzerland (ots/PRNewswire) - - For Non-US and Non-UK Media BASEL, Switzerland, December 6 /PRNewswire/ -- - Abstract Numbers: 325 & LBA-1 BASEL, Switzerland, December 6 /PRNewswire/ -- - Pivotal Phase III Results Suggest MabThera is Set to Change the Face of Chronic Lymphocytic Leukaemia ...
Basel (ots/PRNewswire) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment-Experienced Patients Roche announced today that the European Commission has approved Pegasys(R) (peginterferon alfa-2a (0 KD)) plus Copegus(R) (ribavirin) for the ...
Basel, Switzerland, November 24 (ots/PRNewswire) - FOR NON-UK MEDIA DISTRIBUTION ONLY - Two Phase III Studies to be Presented at World's Major Hematology Meeting Prove MabThera's Benefits in Treating Chronic Lymphocytic Leukemia (CLL) Roche announced today that full results of the pivotal REACH trial ...
Basel, Switzerland, November 20 (ots/PRNewswire) - - Authors Conclude Such Savings may Allow Healthcare Resources to be Reallocated to Other Aspects of Patient Management Switching dialysis patients to once-monthly Mircera(R) from older, more frequently dosed erythropoiesis stimulating agents (ESAs) could ...
Basel, Switzerland, November 13 (ots/PRNewswire) - - Phase III Trial Shows Patients With Advanced Adenocarcinoma of the Lung Have a 45% Better Chance of Survival With Avastin Roche announced today that an exploratory analysis of the pivotal phase III E4599 study demonstrated that Avastin (bevacizumab) ...
Basel, Switzerland, November 10 (ots/PRNewswire) - - Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis Interim study results from 90 renal centres in Germany confirm for the first time that in a real-life setting Mircera(R) ...
Basel, Switzerland, November 1 (ots/PRNewswire) - - Three New Studies Presented at AASLD Demonstrate Efficacy and Safety of Extended Treatment in Non-Responders, Relapsers and Slow-Responders Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by ...